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Association between repeat hospitalization and early
intervention in dialysis patients following hospital
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Dialysis patients have a greater number of hospitalization
events compared to patients without renal failure. Here we
studied the relationship between different post-discharge
interventions and repeat hospitalization in over 126,000
prevalent hemodialysis patients to explore outpatient
strategies that minimize the risk of repeat hospitalization.
The primary outcome was repeat hospitalization within
30 days of discharge. Compared to pre-hospitalization values,
the levels of hemoglobin, albumin, phosphorus, calcium, and
parathyroid hormone and weight were significantly
decreased after hospitalization. Using covariate-adjusted
models, those patients whose hemoglobin was monitored
within the first 7 days after discharge, followed by
modification of their erythropoietin dose had a significantly
reduced risk for repeat-hospitalization when compared to the
patients whose hemoglobin was not checked, nor was the
dose of erythropoietin changed. Similarly, administration
of vitamin D within the 7 days following discharge was
significantly associated with reduced repeat hospitalization
when compared to patients on no vitamin D. Therefore,
it appears that immediate re-evaluation of anemia
management orders and resumption of vitamin D soon
after discharge may be an effective way to reduce repeat
hospitalization.
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Over the past 15 years, the United States Renal Data
System has reported modest improvements in mortality but
stable hospitalization rates for patients on chronic renal
replacement therapy.1 Although new knowledge in dialysis
adequacy,2 anemia management,3 and vitamin D therapy4,5
may have contributed to the reduction in mortality,1
relatively little research has focused on the prevention or
reduction of hospitalization episodes, which has remained
relatively stable at an annual rate of two admissions and 14
hospital days per patient-year.1 Hospitalization remains an
important outcome for the end-stage renal disease (ESRD)
population, partly because patients on dialysis have a
threefold increase in the number of hospitalizations when
compared with the Medicare average. Per-patient per-year
inpatient costs have risen by more than 30% in the past 15
years, and approximately one-third of the $26 billion in total
ESRD expenditures result from hospitalization costs.1
Given the increasing complexity of medical disease and
the continuing focus on reducing hospital length of stay, the
post-hospitalization phase is increasingly being used as an
‘extended period’ for ongoing therapy started in the hospital.
Evidence-based recommendations for the effective transfer
and reevaluation of a post-hospitalized ESRD patient are
almost nonexistent and, increasingly, there is recognition that
this sub-population of post-hospitalized patients may benefit
from additional focused monitoring and intervention.6,7
This study sought to determine the impact of hospitaliza-
tion on commonly accepted core indicators of quality in a
large, diverse population of prevalent patients undergoing
chronic hemodialysis. In the second part of this study, the
relationship between different post-discharge interventions
and repeat hospitalization within 30 days were studied to
explore the possible outpatient strategies that may minimize
the risk of repeat admission to hospital.
RESULTS
Effect of hospitalization
Among incenter patients who received hemodialysis at an
outpatient clinic operated by Fresenius Medical Care North
America in 2007, the hospitalization rate was found to be
2.02 admissions per patient-year (n¼ 162,389 hospitaliza-
tions) and the median length of stay was 5 days. In all, 31% of
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patients in our study cohort had more than one hospitaliza-
tion episode per year. The new hospitalization rate (that is,
hospitalizations not preceded by another within 30 days) was
found to be 1.51 admissions per patient-year (n¼ 121,617
hospitalizations), with 83% of these patients (n¼ 100,835)
returning to a Fresenius facility for hemodialysis within
7 days after discharge from a new hospitalization. A total of
17% of these patients (n¼ 20,782) did not meet this criteria,
of whom 13% were hospitalized for more than 30 days, 36%
had a repeat hospitalization within 7 days, 24% died during
hospitalization, 6% were transferred to a non-Fresenius clinic
or to long-term care, 6% withdrew from dialysis, 3% were
transplanted, 1% had renal function recovery, 0.3% changed
their dialysis modality, and 9% were unknown.
Rates and characteristics of the most prevalent causes for
new hospitalization are displayed in Table 1.
When compared with the most recent pre-hospitalization
values, hemoglobin (mean change±s.e.: 0.5±0.01 g per
100 ml, Po0.0001), albumin (mean change±s.e.: 0.1±
0.002 g per 100 ml, Po0.0001), phosphorus (mean change±
s.e.: 0.3±0.01 mg per 100 ml, Po0.0001), calcium (mean
change±s.e.: 0.1±0.003 mg per 100 ml, Po0.0001), para-
thyroid hormone (PTH) (mean change±s.e.:28±0.2 pg/ml,
Po0.0001), and weight (mean change±s.e.: 0.7±0.01 kg,
Po0.0001) were all found to be decreased on return to
outpatient dialysis after discharge from hospital. The extent of
the change in these parameters was larger with an increasing
length of stay (Figure 1a).
In all, 71.5% of patients had their hemoglobin checked
within the first 7 days after discharge from hospital,
with 23.3% of the patients receiving more EPO than their
pre-hospitalization dose and 5.6% of the patients receiving
less EPO. Figure 1b further shows the prevalence of post-
hospitalization EPO and vitamin D usage by length of stay.
In patients with post-hospitalization hemoglobin moni-
toring, who were found to have a hemoglobin p10 g per
100 ml (20.6% of the population), only 47.3% had their EPO
dose increased within the 7 days after discharge. Likewise,
45.7% of post-hospitalized patients had a hemoglobinp11 g
per 100 ml, with 43.2% of these patients receiving an increase
in their EPO dose, whereas 71.6% of post-hospitalized
patients had a hemoglobin p12 g per 100 ml with only
33.8% of these patients receiving an increase in their EPO
dose.
A total of 7.1% (n¼ 4814 of 68,275) of patients who were
on vitamin D before hospitalization were not on vitamin D in
the 7 days after discharge. 21.7% Of patients returning from
the hospital had their target dry weight modified within a
week after hospital discharge.
Effect of intervention during the post-hospitalization period
Baseline patient characteristics. Baseline patient character-
istics by three independent post-hospitalization interventions
are shown in Table 2a–c. Not surprisingly, patients who had
post-hospitalization changes in their EPO dose or target dry
weight also had a longer hospital length of stay.
Post-hospitalization anemia management. In all, 28.9% of
patients had a hemoglobin drawn and EPO dose modified
within 1 week after discharge from hospital and return to the
facility. Significant differences in the crude risk of repeat
hospitalization were noted between the intervention groups
(Po0.0001): patients with a hemoglobin order and a
subsequent change in EPO dose on return from the hospital
were less likely to have a repeat hospitalization (25.4% risk
for repeat hospitalization) than those with no hemoglobin
monitoring and an unchanged EPO dose (29.7% risk for
repeat hospitalization).
Multivariable survival analysis (Table 3) showed a 16%
(Po0.0001) reduction in the risk for repeat hospitalization
when the EPO dose was modified in tandem with a
hemoglobin order (reference: no hemoglobin order and
keeping the EPO dose the same). Hazard ratios rose steeply
early on after hospital discharge (Figure 2), suggesting that
the effect of early intervention (that is, within 7 days after
hospitalization) was immediate and diminishes over time.
For example, early anemia management decreased the risk of
repeat hospitalization by 28% in the first 2 weeks after
discharge from hospital; however, the hospitalization benefit
decreased to 15% when the follow-up period was extended to
the first 30 days. The trends persisted after correction for a
possible selection bias with a propensity score adjustment
(Table 3), after matching for the treating facility and/or
physician (Table 4), and in 41 of 46 strata in the subgroup
analysis (Figure 3a), with greater benefits seen in patients
who had larger pre- to post- hospitalization decreases in their
hemoglobin level (Figure 3a).
Table 1 |Most prevalent primary diagnosis for new
hospitalization
New
hospitalizations
per patient-
year
Median
length of
stay (days)
Probability
of repeat
hospitali-
zation (%)a
Infection 0.22 7 25.3
Access related 0.14 4 24.1
Volume overload 0.07 4 29.4
Chest pain 0.07 4 28.1
Shortness of breath 0.06 4 30.4
Congestive heart failure 0.05 5 28.8
Cardiovascular diseaseb 0.04 5 26.2
Hypertension 0.03 4 28.0
Nausea and vomiting 0.03 4 30.3
Peptic ulcer disease 0.02 5 24.5
Abdominal pain 0.02 5 29.2
Myocardial infarction 0.02 6 28.5
Fever and chills 0.02 5 27.0
Hypotension 0.02 5 29.0
Weakness 0.02 5 28.3
Altered mental status 0.02 6 31.3
Anemia 0.02 4 31.2
Hyperkalemia 0.02 3 24.3
Coronary artery disease 0.02 5 21.8
Bleeding 0.01 5 23.9
Other causes 0.57 5 26.6
aHospital visit within 30 days after discharge from a new hospitalization.
bExcluding myocardial infarction, congestive heart failure, and coronary artery
disease.
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After stratification by ordinals of post-hospitalization
hemoglobin levels, a statistically significant decrease in repeat
hospitalization was associated with an appropriate adjust-
ment of EPO to achieve a hemoglobin level greater than 10 g
per 100 ml (Figure 4a and b). Patients with a post-
hospitalization hemoglobin p10 g per 100 ml had a 6%
(P¼ 0.05) decreased risk of repeat hospitalization when the
EPO dose was increased (vs. same EPO dose) within the 7
days after hospitalization. Conversely, decreasing the EPO
dose (vs. same EPO dose) when the post-hospitalization
hemoglobin level was p11 g per 100 ml increased the risk of
repeat hospitalization by 34% (Po0.0001).
Post-hospitalization vitamin D therapy. Patients adminis-
tered vitamin D in the immediate post-hospitalization period
also had a decreased risk for repeat hospitalization (26.0 vs
28.4% crude risk for repeat hospitalization, Po0.0001).
After covariate adjustment, the administration of vitamin
D decreased the risk for repeat hospitalization by 6%
(Po0.0001) when compared with no vitamin D (Table 3).
Moreover, discontinuing vitamin D on return to dialysis (vs
continuing vitamin D) in patients who were on it before
hospitalization (4814 of 68,275 patients had vitamin D
discontinued) increased the risk of repeat hospitalization by
9% (P¼ 0.001).
Similar to earlier findings on anemia management, the
decrease in the risk of repeat hospitalization with the timely
institution of vitamin D therapy was achieved early
(Figure 2). The results also withstood matched (Table 4),
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Figure 1 |Change in patient characteristics associated with hospitalization by length of hospital stay. (a) Impact of hospitalization on
hemoglobin, albumin, and weight by length of stay. (b) Impact of hospitalization on the prevalence of EPO and vitamin D usage by length
of stay. Note: vitamin D discontinued patients are patients who were on vitamin D before hospitalization and did not receive any vitamin D
within the 7 days after hospitalization. Because of smaller sample sizes, patients with a length of stay between 8 and 14 days and between
15 and 30 days were grouped together.
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propensity score-adjusted (Table 3), and stratified (all 46
stratum shown in Figure 3b) sensitivity analyses. No dose-
dependent benefit on repeat hospitalization was observed in
the case of vitamin D (P-trend¼ 0.13).
Post-hospitalization target dry-weight management. Pati-
ents who had their target post-dialysis weight (estimated dry
weight) modified within the first 7 days after hospitalization
had a lower crude risk for repeat hospitalization (25.7% risk
for repeat hospitalization) than did patients who maintained
the same dry-weight target after discharge from hospital
(27.1% risk for repeat hospitalization). Estimated dry weight
modification (vs no modification) was associated with a 6%
decrease (P¼ 0.0001) in the adjusted risk for repeat
hospitalization (Table 3). The effect became statistically
insignificant once propensity score adjustment was added to
the model (P¼ 0.11).
Interaction between post-hospitalization anemia manage-
ment, vitamin D therapy, and target dry-weight modification.
Cross-product terms between hemoglobin monitoring and
EPO adjustment, vitamin D administration, and dry-weight
Table 2a | Baseline patient characteristics by
post-hospitalization anemia management status
No Hgb, no EPO
dose modification
(reference)
Hgb order,
EPO dose
modification P-value
n 19,782 29,087
Age (years) 62.3 (0.1) 63.2 (0.08) o0.0001
Gender (%male) 50.7 (0.2) 49.4 (0.2) 0.004
Race
African American (%) 41.2 (0.2) 38.4 (0.2)
Other (%) 7.0 (0.1) 6.8 (0.1)
Caucasian (%) 51.8 (0.2) 54.8 (0.2) o0.0001
Charlson score 5.4 (0.01) 5.5 (0.01) o0.0001
Vintage (years) 3.4 (0.02) 3.4 (0.02) 0.55
Access
AVF (%) 35.3 (0.2) 35.0 (0.2)
Catheter (%) 38.3 (0.2) 39.2 (0.2)
Graft (%) 26.0 (0.1) 25.5 (0.1)
Unknown (%) 0.4 (0.0) 0.2 (0.02) 0.003
Length of stay (days) 3.5 (0.02) 5.9 (0.03) o0.0001
Pre-hospitalization values
Albumin (g per 100ml) 3.7 (0.003) 3.7 (0.003) 0.75
Hgb (g per 100ml) 11.7 (0.01) 11.9 (0.01) o0.0001
EPO (1000U) 8.9 (0.06) 7.5 (0.04) o0.0001
Vitamin D (% use) 68.2 (0.2) 66.4 (0.2) o0.0001
Phosphorus
(mg per 100ml)
5.5 (0.01) 5.4 (0.01) 0.0009
PTH (pg/ml) 396 (3) 373 (2) o0.0001
Weight (kg) 77.6 (0.1) 75.8 (0.1) o0.0001
Table 2b | Baseline patient characteristics by
post-hospitalization vitamin D use
No vitamin D
order (reference)
Vitamin D
order P-value
n 68,658 32,177
Age (years) 62.6 (0.08) 62.7 (0.05) 0.19
Gender (% male) 50.0 (0.1) 49.9 (0.1) 0.82
Race
African American (%) 30.4 (0.1) 45.4 (0.1)
Other (%) 6.6 (0.07) 6.9 (0.08)
Caucasian (%) 63.1 (0.1) 47.7 (0.1) o0.0001
Charlson score 5.4 (0.01) 5.5 (0.008) 0.0001
Vintage (years) 3.1 (0.02) 3.6 (0.01) o0.0001
Access
AVF (%) 32.6 (0.1) 36.2 (0.1)
Catheter (%) 44.9 (0.1) 35.7 (0.1)
Graft (%) 22.0 (0.1) 27.8 (0.1)
Unknown (%) 0.4 (0.02) 0.2 (0.01) o0.0001
Length of stay (days) 5.0 (0.02) 4.6 (0.01) o0.0001
Pre-hospitalization values
Albumin (g per 100ml) 3.6 (0.003) 3.7 (0.002) o0.0001
Hgb (g per 100ml) 11.8 (0.01) 11.8 (0.006) 0.92
EPO (1000U) 9.1 (0.04) 8.5 (0.03) o0.0001
Vitamin D (% use) 15.0 (0.1) 92.4 (0.08) o0.0001
Phosphorus
(mg per 100ml)
5.5 (0.01) 5.4 (0.006) o0.0001
PTH (pg/ml) 310 (2) 419 (1) o0.0001
Weight (kg) 75.1 (0.1) 77.7 (0.08) o0.0001
Table 2c | Baseline patient characteristics by modification of
post-hospitalization dry weight
Same target
dry weight
(reference)
Modification
of target
dry weight P-value
n 78,951 21,884
Age (years) 62.4 (0.05) 63.8 (0.1) o0.0001
Gender (%male) 50.0 (0.1) 49.7 (0.1) 0.42
Race
African American (%) 41.2 (0.1) 38.7 (0.1)
Other (%) 6.8 (0.08) 6.6 (0.07)
Caucasian (%) 52.0 (0.1) 54.8 (0.1) o0.0001
Charlson score 5.4 (0.008) 5.5 (0.01) o0.0001
Vintage (years) 3.5 (0.01) 3.4 (0.02) 0.001
Access
AVF (%) 34.9 (0.1) 35.6 (0.1)
Catheter (%) 38.6 (0.1) 38.9 (0.1)
Graft (%) 26.2 (0.1) 25.2 (0.1)
Unknown (%) 0.3 (0.01) 0.3 (0.01) 0.02
Length of stay (days) 4.4 (0.01) 5.8 (0.03) o0.0001
Pre-hospitalization values
Albumin (g per 100ml) 3.7 (0.002) 3.6 (0.003) o0.0001
Hgb (g per 100ml) 11.8 (0.006) 11.6 (0.01) o0.0001
EPO (1000U) 8.5 (0.03) 9.1 (0.05) o0.0001
Vitamin D (% use) 67.8 (0.1) 67.4 (0.1) 0.22
Phosphorus (mg per 100ml) 5.5 (0.007) 5.3 (0.01) o0.0001
PTH (pg/ml) 390 (1) 372 (2) o0.0001
Weight (kg) 76.9 (0.07) 76.9 (0.1) 0.98
EPO, epogen; Hgb, hemoglobin; PTH, parathyroid hormone.
Results expressed as mean (s.e.).
This table compares the baseline patient characteristics of the study cohort by three
independent post-hospitalization interventions (EPO dose adjustment + Hgb vs
same EPO dose + no Hgb; vitamin D vs no vitamin D; dry weight modification vs
no modification); P-values compare the individual characteristics of the patients
who receive intervention after hospitalization with patients who do not receive
intervention in the areas of anemia management, vitamin D therapy, and dry weight
assessment.
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modification were insignificant (P40.05), indicating that
there was no evidence of effect modification between anemia
intervention, the administration of vitamin D, and the
adjustment of target dry weight on the risk of repeat
hospitalization.
DISCUSSION
This retrospective study in a large ESRD population demons-
trated that hospitalization was associated with significant
decreases in albumin, hemoglobin, and phosphorus, which
become worse with increasing length of stay. Appropriate
anemia management and the administration of vitamin D
within the first 7 days after discharge from hospital and
on return to a dialysis facility were each independently
associated with a decreased risk of repeat hospitalization.
When examined over a 1-year period, the clinical significance
of early intervention is likely to be greater, given that the
benefit is potentially cumulative in patients who experience
multiple hospitalizations per year (430% of the study
cohort).
Table 3 | Association between post-hospitalization intervention and the risk of repeat hospitalization
Unadjusted model
(n=100,835)
Adjusted modela
(n=86,581)
Adjusted model with propensity
scoringb (n=86,581)
Model 1 (post-hospitalization laboratory monitoring only)
Hemoglobin (ordered vs not ordered) 0.82 (0.80–0.85) 0.83 (0.80–0.86) 0.84 (0.81–0.87)
Calcium (ordered vs not ordered) 0.88 (0.79–0.98) 0.89 (0.80–1.00) 0.92 (0.81–1.04)
Phosphorus (ordered vs not ordered) 1.09 (0.98–1.22) 1.07 (0.95–1.20) 1.04 (0.92–1.18)
Parathyroid hormone (ordered vs not ordered) 1.03 (0.99–1.06) 1.03 (0.99–1.07) 1.04 (1.00–1.08)
Model 2 (post-hospitalization intervention only)
Modification of EPO dose post-hospitalization (vs same) 0.99 (0.96–1.01) 1.02 (0.99–1.05) 1.04 (1.01–1.08)
Vitamin D post-hospitalization (vs none) 0.90 (0.87–0.92) 0.94 (0.92–0.98) 0.94 (0.91–0.97)
Modification of dry weight post-hospitalization (vs none) 0.94 (0.91–0.96) 0.93 (0.90–0.97) 0.97 (0.94–1.01)
Model 3 (post-hospitalization laboratory monitoring and intervention)
Hemoglobin ordered + modification of EPO dose (vs no hemoglobin
ordered + same EPO dose)
0.81 (0.79–0.84) 0.84 (0.81–0.88) 0.85 (0.81–0.89)
Vitamin D post-hospitalization (vs none) 0.90 (0.87–0.92) 0.94 (0.92–0.97) 0.94 (0.91–0.97)
Modification of dry weight post-hospitalization (vs no modification) 0.94 (0.91–0.97) 0.94 (0.91–0.97) 0.97 (0.94–1.01)
aModel adjusted for the following covariates: age, gender, race, Charlson comorbidity index, length of stay, vintage, access, diabetic status, pre-hospitalization laboratory
values (hemoglobin, phosphorus, parathyroid hormone, calcium, and albumin), and the 20 most prevalent causes for hospitalization.
bModel adjusted for covariates and propensity score (components of the propensity score: age, gender, race, Charlson comorbidity index, length of stay, vintage, access,
diabetic status, pre-hospitalization laboratory values (hemoglobin, phosphorus, parathyroid hormone, calcium, and albumin), and the 20 most prevalent causes for
hospitalization).
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Figure 2 |Hazard ratios for repeat hospitalization within the specified number of days after discharge from hospital. This graph
illustrates the time-sensitive relationship between early post-hospitalization anemia management and vitamin D administration with the
risk of repeat hospitalization. Hazard ratios become less profound over time, which suggest excess repeat hospitalizations when anemia
management or vitamin D administration is delayed. Hazard ratios have been covariate and propensity-score adjusted.
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Table 4 | Hazard ratios for repeat hospitalization after matching on the specified variables
Matched variablea n Unadjusted model Adjusted modelb Adjusted model + propensity scoringc
HR for hgb order + EPO dose modification (vs no hgb order + same EPO dose)
Facility 33,054 0.82 (0.79–0.85) 0.86 (0.83–0.91) 0.90 (0.82–0.99)d
Physician 33,160 0.81 (0.78–0.84) 0.84 (0.81–0.88) 0.88 (0.80–0.97)d
Facility + physician 27,096 0.82 (0.78–0.85) 0.85 (0.81–0.90) 0.92 (0.83–1.02)d
HR for vitamin D (vs no vitamin D)
Facility 60,552 0.90 (0.87–0.93) 0.95 (0.92–0.98) 0.95 (0.92–0.98)e
Physician 59,510 0.90 (0.88–0.93) 0.95 (0.92–0.98) 0.96 (0.92–0.99)e
Facility + physician 51,786 0.91 (0.88–0.94) 0.96 (0.93–1.00) 0.97 (0.93–1.00)e
EPO epogen; hgb, hemoglobin; HR, Hazard ratio.
aEach ‘vitamin D’ patient was paired with a ‘non-vitamin D’ patient in the same facility, under the care of the same attending nephrologist, and then under the care of the
same attending nephrologist in the same facility. This ensured that all facility and/or physician factors in the case and control groups were balanced in the analysis.
bModel adjusted for the following covariates: age, gender, race, Charlson comorbidity index, length of stay, vintage, access, diabetic status, pre-hospitalization laboratory
values (hgb, phosphorus, parathyroid hormone, calcium, and albumin), and the 20 most prevalent causes for hospitalization.
cModel adjusted for covariates and propensity score (components of the propensity score: age, gender, race, Charlson comorbidity index, length of stay, vintage, access,
diabetic status, pre-hospitalization laboratory values (hgb, phosphorus, parathyroid hormone, calcium, and albumin), and the 20 most prevalent causes for hospitalization).
dc-Statistic for propensity score=0.86.
ec-Statistic for propensity score=0.67.
Age (years) Albumin (g per 100 ml)
<3.4 (n =16,196)
3.4 – 3.65 (n =17,843)
3.7 – 3.8 (n =17,434)
2.0
3.5
3.9 – 4 (n =16,909)
>4 (n =18,187)
>0.4 decrease (n =7103)
0.2 – 0.4 decrease (n =5457)
0.2 – 0.0 decrease (n =5972)
0 – 0.1 increase (n =7147)
>0.1 increase (n =5880)
Hemoglobin (g per 100 ml)
<10.6 (n =16,585)
10.6 – 11.4 (n =16,955)
11.5 – 12.2 (n =19,149)
12.3 – 13 (n =16,187)
>13 (n =17,693)
Pre-to-post hospitalization change in hgb (g per 100 ml)
>1.6 decrease (n =12,604)
1.6 – 0.8 decrease (n =11,771)
0.8 – 0.2 decrease (n =12,711)
0.2 decrease – 0.5 increase (n =12,741)
>0.5 increase (n =11,321)
Pre-to-post hospitalization change in albumin (g per 100 ml)
<50.3 (n =17,313)
50.3 – 59.8 (n =17,317)
59.9 – 67.8 (n =17,311)
67.9 – 76.4 (n =17,315)
>76.4 (n =17,313)
Gender
Male (n =43,373)
Female (n =43,196)
Race
African American (n =35,312)
Other (n =5,896)
Caucasian (n =45,361)
Diabetes
Diabetic (n =57,395)
Non-diabetic (n =29,174)
Length of stay (days)
Charlson score
2 – 3 (n =18,420)
4 – 5 (n =26,505)
6 – 7 (n =28,888)
8 – 19 (n =12,756)
EPO dose (1000 U)
<1.8 (n =17,499)
1.8 – 4.2 (n =17,318)
4.3 – 7.7 (n =17,163)
7.8 – 13.7 (n =17,279)
>13.7 (n =17,310)
0.3 0.5 0.7 0.9 1.1 1.3 1.5 1.7
Favors hgb order and
change in EPO dose
Favors no hgb order and
same EPO dose
Favors hgb order and
change in EPO dose
Favors no hgb order and
same EPO dose
0.6 0.7 0.8 0.9 1 1.1
≤2 (n =22,898)
3 (n =12,759)
4–5 (n =19,696)
6–8 (n =15,609)
≥9 (n =15,607)
Figure 3 |Hazard ratios for repeat hospitalization associated with early post-hospitalization intervention, stratified by
characteristics of the patient. (a) Hazard ratios for repeat hospitalization associated with post-hospitalization hemoglobin
monitoringþ EPO dose modification (vs no hemoglobin monitoring and the same EPO dose), with stratification according to patient
characteristics. (b) Hazard ratios for repeat hospitalization associated with vitamin D administration (vs none), with stratification according
to patient characteristics.
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The rate of hospitalization is high for all dialysis patients
who, as a group, have a high prevalence of comorbid
conditions and treatment-related complications.1,8–10 The
transition from being an inpatient in a hospital to going back
to the facility is an important period for patients to recover
from a possible acute decline in their baseline health status.
Unfortunately, a discontinuity between inpatient and out-
patient care is common,11 which can hinder the recovery
process through a preventable medication error,11 adverse
events,12–14 and re-hospitalization.11,15 In many cases, dialysis
patients returning to their outpatient facility have their
routine orders reinstated (‘resume previous orders’) with no
additional modification or monitoring. In fact, post-
hospitalized patients with no EPO dose modification and
no hemoglobin monitoring had a risk of repeat hospitaliza-
tion that was equivalent when compared to anemic post-
hospitalized patients (hemoglobino10 g per 100 ml) who do
not receive an increase in their EPO dose (Hazard
ratio¼ 0.97; 95% confidence interval 0.92–1.03). Although
an increased physician–patient contact time has been shown
to reduce morbidity and mortality of dialysis patients in
general, frequent patient evaluation, specifically after hospi-
talization, remains unproven.16–18 Using physician’s orders,
this study examined the possible impact of timely medical
intervention on the risk of repeat hospitalization. The results
suggest that the appropriate and timely reassessment of a
post-hospitalized dialysis patient may be an effective strategy
to interrupt the cascade of repeated hospitalizations and the
subsequent downward spiral.19
Overall, the peri-hospitalization period could be described
by an acute inflammation-malnutrition syndrome character-
ized by significant decreases in weight, albumin, and
phosphorus (followed by decrements in PTH values), with
increasing EPO resistance. Although the decrease in phos-
phorus may be a beneficial ‘unintended consequence’ of
hospitalization, particularly in patients with hyperphospha-
temia, it is important to analyze the factors that may have led
to or are associated with this improvement: if it is due to an
improved prescription or compliance with phosphate
binders, it is indeed a beneficial outcome; however, if it
Age (years)
<50.3 (n=17,313)
50.3 – 59.8 (n=17,317)
59.9 – 67.8 (n=17,311)
67.9 –76.4 (n=17,315)
>76.4 (n =17,313)
Albumin (g per 100 ml)
<3.4 (n=16,196)
3.4 – 3.65 (n=17,843)
3.7 – 3.8 (n=17,434)
3.9 – 4 (n=16,909)
>4 (n=18,187)
Pre-to post-hospitalization change in albumin (g per 100 ml)
>0.4 decrease (n=7103)
0.2 – 0.4 decrease (n=5457)
0.2 – 0.0 decrease (n=5972)
0 – 0.2 increase (n=7147)
>0.1 increase (n=5880)
Parathyroid hormone (PTH) (pg per 100 ml)
<130 (n =17,324)
130 – 217 (n=17,304)
218 – 322 (n=17,309)
323 – 539 (n=17,317)
≥540 (n=17,315)
Pre-to post-hospitalization change in PTH (pg per 100 ml)
>175 decrease (n=4451)
175 – 46 decrease (n=4494)
46 decrease - 27 increase (n=4514)
27 – 135 increase (n=4521)
>135 increase (n=4439)
Gender
Male (n=43,373)
Female (n =43,196)
Race
African American (n=35,312)
Other (n=5896)
Caucasian (n=45,361)
Diabetes
Diabetic (n=57,395)
Non-diabetic (n =29,174)
Length of stay (days)
≤2 (n=22,898)
3 (n=12,759)
4 – 5 (n=19,696)
6 – 8 (n=15,609)
≥9 (n=15,607)
Charlson score
2 – 3 (n=18,420)
4 – 5 (n=26,505)
6 – 7 (n =28,888)
8 – 19 (n =12,756)
Phosphorus (mg per 100 ml)
<4 (n=17,305)
4 – 4.75 (n=16,489)
4.8 – 5.6 (n=18,509)
5.7 – 6.7 (n=16,497)
>6.7 (n=17,769)
0.7 0.8 0.9 1.11
Favors
vitamin D
Favors
no vitamin D
0.7 0.8 0.9 1.1 1.21
Favors
vitamin D
Favors
no vitamin D
Figure 3 | Continued.
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reflects a decreased oral intake, then it may not be.
Unfortunately, the Fresenius electronic medical records are
not linked to hospital systems, and we did not have access to
information about the patient when in the hospital to
incorporate into the analysis.
This study confirms that hospitalization in ESRD patients
is associated with a significant decline in hemoglobin, as
reported in two previous analyses.20,21 Lower hemoglobin
levels have been shown to increase the risk of hospital
admissions, although the optimal target hemoglobin level
remains somewhat controversial. This study found that
patients with a post-hospitalization hemoglobin level p10 g
per 100 ml (14% of patients discharged from hospital)
significantly benefited from an increase in the EPO dose on
discharge from hospital, which is consistent with the latest
Food and Drug Administration recommendation for anemia
patients with chronic renal failure.22 Given the number of
patients with such a hemoglobin level, routine hemoglobin
monitoring on a return to dialysis would seem to be a
reasonable first strategy to decrease the risk of repeat
hospitalization.
This study also found that patients who did not receive
vitamin D after hospitalization had worse outcomes when
compared with patients who did receive vitamin D. The risk
of repeat hospitalization was greater in patients who had their
vitamin D discontinued after discharge from hospital.
Although the changes in the mineral-metabolism parameters
(calcium, phosphorus, PTH) were modest, they were also
decrements and unlikely to be viewed as a contraindication
to restarting vitamin D therapy on return from hospital.
Overall, these results are consistent with current studies that
demonstrate a survival benefit with vitamin D therapy,5
which, in the aggregate, suggest that the impact of vitamin D
is more pervasive than being merely for the control of the
PTH in a dialysis population23
Although the reduction in the frequency of repeat hospitali-
zation with changes in the EPO dose and with the reinstitution
of vitamin D was statistically significant, we should never-
theless emphasize that these are not our current recommenda-
tions, which should await prospective clinical trials.
This study also highlights the fact that hospitalization is
associated with significant decreases in serum albumin and
weight; nevertheless, it was not possible to explore the impact
of post-hospitalization interventions to ameliorate malnutri-
tion and inflammation because such data were not collected
at the time of the study and interventions to address this are
not well defined. However, considering the robust relation-
ship between albumin concentration with hospitalization24–26
and mortality,27 it is reasonable to conclude that early
intervention—for example, through the encouragement of
oral intake, use of nutritional supplements, treatment of any
infection, and avoidance of catheters—may also help in
reducing the rate of repeat hospitalization in such patients.
Our study also did not report a significant association
between repeat hospitalization with target dry-weight
modification or with the monitoring of calcium, phosphorus,
and the PTH. Consequently, clinical judgment should be
used for mineral-metabolism monitoring and volume
management in the immediate post-hospitalization period.
Potential residual confounding from unmeasured patient
characteristics is likely to be the study’s biggest limitation.
For example, there was no charting of a phosphate binder
prescription that could have confounded the effect of vitamin
D. We also could not formally quantify a patient’s true
volume status to determine how a dilution from the excess
extracellular volume could have affected the decrement in
laboratory parameters associated with hospitalization. Con-
founding by indication was likely to be minimal, given that
sicker patients who are discharged from hospital are more
Post-hospitalization hemoglobin (g per 100 ml)
Post-hospitalization hemoglobin (g per 100 ml)
1.39
1.30
1.07
≤10 (n=12,442)
10–11 (n=13,628)
11–12 (n=17,660)
12–13 (n=10,688)
>13 (n=6730)
≤10 (n=12,442)
10–11 (n=13,628)
11–12 (n=17,660)
12–13 (n=10,688)
>13 (n=6730)
1.06
1.01
0.94
0.98
1.01
1.13
0.96
0.7 0.8 1.00.9 1.1 1.2 1.3
0.9 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7
Favors EPO
dose decrease
Favors EPO
dose same
Favors EPO
dose increase
Favors EPO
dose same
Figure 4 |Hazard ratios for repeat hospitalization associated
with increasing or decreasing EPO dose, stratified by post-
hospitalization hemoglobin level. (a) Adjusted hazard ratios for
repeat hospitalization with a decrease in pre- to post-EPO dose (vs
same EPO dose) stratified according to post-hospitalization
hemoglobin level. (b) Adjusted hazard ratios for repeat
hospitalization with an increase in pre- to post-EPO dose (vs same
EPO dose) stratified according to pre to post–hospitalization
hemoglobin level. a and b suggest the adjustment of post-
hospitalization EPO dose to target a hemoglobin level 410mg
per 100ml. In patients with a post-hospitalization hemoglobin
level p10 g per 100ml, an increase in EPO dose was associated
with a decreased risk of repeat hospitalization (b). Decreasing EPO
dose was associated with an increased risk of repeat
hospitalization in patients with a post-hospitalization hemoglobin
level p11 g per 100ml (a). No statistically significant relationship
could be demonstrated between EPO dose adjustment and
repeat hospitalization in patients with a post-hospitalization
hemoglobin of 11 g per 100ml or greater. Hazard ratios are
covariate and propensity-score adjusted.
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likely to receive early intervention, which could bias the result
toward the null hypothesis. Finally, changes in the Epogen
package insert guidelines by the Food and Drug Adminis-
tration or the Erythropoietin-monitoring policy (EMP) by
CMS during 2007 may have also contributed to the residual
confounding.
In conclusion, hospitalization represents a change of
patient status, which impacts laboratory markers that are
associated with mortality in ESRD. Although the adminis-
tration of vitamin D and the proper treatment of anemia are
known to improve survival, this study suggests that the
timely evaluation of these therapies, as examples of post-
hospitalization care, may result in a significant reduction in
the risk of repeat hospitalization.
MATERIALS AND METHODS
Study population
A retrospective cohort study was conducted that enrolled all
prevalent, outpatient hemodialysis patients at the Fresenius Medical
Care North America from 1 January 2007 to 31 December 2007
(n¼ 80, 578 patient years). All data for the study were derived from
the Fresenius clinical data systems, which prospectively collect
laboratory, medication, demographic, hospitalization, and comor-
bidity information for all patients receiving chronic renal replace-
ment therapy in over 1500 clinics in the United States.
Patients were eligible for the analysis if they were receiving
outpatient hemodialysis at the time of new hospitalization (see
below) and returned to a Fresenius facility for outpatient
hemodialysis within 7 days after discharge from hospital (immediate
post-hospitalization period). The cohort represented a patient
population in which health-care professionals would have an
adequate opportunity to evaluate a recently hospitalized patient
with laboratory testing and modify orders to meet or improve
quality outcome parameters as suggested by the Kidney Disease
Outcomes Quality Initiative (K/DOQI).28
Patients whose hospital length of stay was greater than 30 days
were excluded as these patients were discharged from the dialysis
facility with a closure of their active hospitalization record as
per company policy (1.3% of hospitalization episodes).
Hospitalization, baseline characteristics, and exposures
For the purpose of this study, new hospitalization was defined as a
hospital admission that was not preceded by a previous hospital
encounter within the past 30 days. The immediate post-hospitaliza-
tion period was defined as the 7-day period immediately after a
patient was discharged from the hospital, during which time, any
intervention in the treatment of anemia, administration of vitamin
D, and change in the target dry weight was documented. The impact
of these interventions on repeat hospitalization, defined as a
hospitalization admission within 30 days of discharge from the
most recent hospitalization, was sought.
The documentation of hospitalization data (hospital admission date,
length of stay, and primary and secondary hospitalization diagnosis) in
the Fresenius Medical Care clinical data system was reconciled at the
time of patient discharge. Primary and secondary discharge diagnoses
were obtained from physician-written discharge summaries. Details of
the database can be found in previous publications.29,30
During the study period, Fresenius Medical Care maintained a
post-hospitalization policy that required physician’s reconciliation
of all outpatient orders when patients returned to the dialysis facility
after more than 1 week of hospitalization. Most laboratory
monitoring occurred at regular monthly intervals (and in some
facilities, hemoglobin was ordered routinely every 2 weeks), and
additional laboratory monitoring after a hospitalization was at the
request of the treating nephrologist.
Baseline patient characteristics and laboratory values were
defined as the most recent reading within 30 days before a new
hospitalization event. Post-hospitalization interventions, laboratory
readings, and treatment orders were evaluated within 7 days
immediately after the discharge from hospital and return to facility.
An analysis comparing data at 30 days and 60 days before a new
hospitalization did not show a significant difference (not shown).
The hospitalization rate was calculated by dividing the total
number of hospital admissions over the total number of patient
years of incenter hemodialysis at Fresenius in 2007. The denomi-
nator did not include days when the patient was in hospital.
Impact of hospitalization on laboratory, treatment, and
process parameters
To determine the impact of hospitalization on subsequent
laboratory and treatment parameters, the absolute and percent
change in albumin, hemoglobin, calcium, phosphorus, PTH, dialysis
weight, and EPO dose, which occurred after a new hospitalization,
were calculated for each patient. On average, laboratory readings
were measured 14 days before hospitalization and 3 days after
discharge from hospital. Paired t-tests were used to determine if
there was a significant change in the last value measured before
hospital admission, with the value measured in the 7 days after
discharge from hospitalization. The extent of change (pre- to post-
hospitalization) was calculated for hospitalizations of differing
lengths of stay. Owing to smaller sample sizes, patients with a length
of stay between 8 and 14 days and between 15 and 30 days were
grouped together.
Impact of intervention during the post-hospitalization period
on repeat hospitalization: primary analysis
The primary outcome of the intention-to-treat analysis was the
extent of repeat hospitalization (hospitalization within 30 days of an
earlier admission). Three separate Cox regression analyses were
performed to test whether there was an association between repeat
hospitalization and interventions that occurred in the 7 days after
discharge from hospital. More specifically, we determined the
association between repeat hospitalization, with the following
predictor variables entered into the survival equation: (Model 1)
hemoglobin (ordered within 7 days after hospitalization vs not
ordered), calcium (ordered vs not ordered), phosphorus (ordered vs
not ordered), and PTH (ordered vs not ordered); (Model 2)
EPO dose modification (yes vs no), vitamin D administration
(yes vs no), and target dry-weight change (yes vs no) within 7 days
after hospitalization; and (Model 3) ordering of post-hospitalization
hemoglobin in tandem with EPO dose modification (vs no
hemoglobin order and carrying over pre-hospitalization EPO dose),
vitamin D administration (yes vs no), and target dry-weight change
(yes vs no) within the 7 days after hospitalization.
Hazard ratios with 95% confidence intervals were calculated for
our predictor variables using Cox models that were unadjusted and
then adjusted for baseline covariates: age (years), gender, race
(Caucasian, African American, others), access (fistula, graft,
catheter, unknown), the Charlson comorbidity index,31–33 vintage,
primary hospital discharge diagnosis, length of stay, diabetic status,
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and pre-hospitalization values for albumin, hemoglobin, calcium,
phosphorus, and PTH. A robust sandwich estimator of variance34
was used to correct for correlations of observations within each
patient over time as the same patient could have multiple new
hospitalizations with repeated enrollment in the study. Cross-
product terms between EPO modification, vitamin D administra-
tion, and dry-weight modification were entered into the model to
detect significant interaction effects.
Impact of intervention during the post-hospitalization period
on repeat hospitalization: sensitivity analysis
Several follow-up analyses were also carried out to validate the
findings of our primary analysis. To account for potential
unmeasured confounding and selection bias effects, propensity
score-based risk-adjustment for multiple groups35,36 was imple-
mented. To quantify the degree of possible bias, multinomial logistic
regression was initially used to model the probability of intervention
as a function of 15 variables and the 20 most prevalent causes of
hospitalization. The probability for treatment was incorporated into
our Cox models as inverse weights to correct for possible
confounding by indication.37,38
To account for potential bias from unmeasurable confounders
from the treating physician or facility,39,40 each case (hemoglobin
order with EPO modification) was matched to a control (no
hemoglobin order with the same EPO dose) from the same dialysis
unit and/or nephrologist. Unadjusted and covariate-adjusted hazard
ratios for repeat hospitalization were then determined for the
matched cohort with weighting by propensity for intervention.35
Stratum-specific hazard ratios by prespecified categories (base-
line characteristics and by the degree of pre- to post-hospitalization
change in albumin, hemoglobin, and PTH) were also determined to
examine the effectiveness by different subgroups. P for trend was
calculated by quintiles of vitamin D dose to determine the
dose–response relationship between repeat hospitalization and
vitamin D dose in users. Doxercalciferol and calcitriol doses were
converted into their paricalcitol equivalent41 for this analysis. All
statistical analyses were carried out using SAS version 9.1 (Cary,
North Carolina).
DISCLOSURE
Dr Chan, Lazarus, Wingard, and Hakim are employees of Fresenius
Medical Care North America.
ACKNOWLEDGMENTS
We thank Dr Norma Ofsthun for her feedback. We express
appreciation to the staff in over 1500 Fresenius dialysis clinics who
continually make great efforts to ensure the accurate charting of
clinical data in the computer system.
REFERENCES
1. Atlas of chronic kidney disease and end-stage renal disease in the United
States. Renal Data Systems. USRDS 2007 Annual Data Report: National
Institutes of Diabetes and Digestive and Kidney Disease. Bethesda, MD,
2007.
2. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and
membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347:
2010–2019.
3. Besarab A, Bolton WK, Browne JK et al. The effects of normal as
compared with low hematocrit values in patients with cardiac disease
who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339:
584–590.
4. Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing
hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;
349: 446–456.
5. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and
hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005;
16: 1115–1125.
6. Jack BW, Chetty VK, Anthony D et al. A reengineered hospital discharge
program to decrease rehospitalization: a randomized trial. Ann Intern Med
2009; 150: 178–187.
7. Kripalani S, Jackson AT, Schnipper JL et al. Promoting effective transitions
of care at hospital discharge: a review of key issues for hospitalists.
J Hosp Med 2007; 2: 314–323.
8. Woods JD, Port FK. The impact of vascular access for haemodialysis on
patient morbidity and mortality. Nephrol Dial Transplant 1997; 12:
657–659.
9. Port FK. Morbidity and mortality in dialysis patients. Kidney Int 1994; 46:
1728–1737.
10. Dhingra RK, Young EW, Hulbert-Shearon TE et al. Type of vascular access
and mortality in U.S. hemodialysis patients. Kidney Int 2001; 60: 1443–1451.
11. Moore C, Wisnivesky J, Williams S et al. Medical errors related to
discontinuity of care from an inpatient to an outpatient setting.
J Gen Intern Med 2003; 18: 646–651.
12. Forster AJ, Murff HJ, Peterson JF et al. Adverse drug events occurring
following hospital discharge. J Gen Intern Med 2005; 20: 317–323.
13. Forster AJ, Clark HD, Menard A et al. Adverse events among medical
patients after discharge from hospital. CMAJ 2004; 170: 345–349.
14. Forster AJ, Murff HJ, Peterson JF et al. The incidence and severity of
adverse events affecting patients after discharge from the hospital.
Ann Intern Med 2003; 138: 161–167.
15. Coleman EA, Mahoney E, Parry C. Assessing the quality of preparation for
posthospital care from the patient’s perspective: the care transitions
measure. Med Care 2005; 43: 246–255.
16. Mentari EK, DeOreo PB, O’Connor AS et al. Changes in Medicare
reimbursement and patient-nephrologist visits, quality of care, and
health-related quality of life. Am J Kidney Dis 2005; 46: 621–627.
17. Plantinga LC, Fink NE, Sadler JH et al. Frequency of patient-physician
contact and patient outcomes in hemodialysis care. J Am Soc Nephrol
2004; 15: 210–218.
18. Plantinga LC, Fink NE, Jaar BG et al. Frequency of sit-down patient care
rounds, attainment of clinical performance targets, hospitalization, and
mortality in hemodialysis patients. J Am Soc Nephrol 2004; 15: 3144–3153.
19. Lazarus JM. Recommended criteria for initiating and discontinuing intra-
dialytic parenteral nutrition therapy. Am J Kidney Dis 1999; 33: 211–216.
20. Nissenson AR, Dylan ML, Griffiths RI et al. Septicemia in patients with
ESRD is associated with decreased hematocrit and increased use of
erythropoietin. Clin J Am Soc Nephrol 2006; 1: 505–510.
21. Muhammad YS, Leiser J, Moliteris BA. Erythopoietin requirements
increase following hospitalization in end-stage renal disease patients.
Am J Nephrol 2001; 21: 390–396.
22. U.S.Food and Drug Administration. Information for Healthcare
Professionals: Erythropoiesis Stimulating Agents (ESA). http://
www.fda.gov/Cder/Drug/InfoSheets/HCP/RHE200711HCP.htm.
11-8-2007. Ref Type: Electronic Citation.
23. Noordzij M, Korevaar JC, Boeschoten EW et al. The Kidney Disease
Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and
Disease in CKD: association with mortality in dialysis patients. Am J Kidney
Dis 2005; 46: 925–932.
24. Chertow GM, Goldstein-Fuchs DJ, Lazarus JM et al. Prealbumin, mortality,
and cause-specific hospitalization in hemodialysis patients. Kidney Int
2005; 68: 2794–2800.
25. Plantinga LC, Fink NE, Jaar BG et al. Attainment of clinical performance
targets and improvement in clinical outcomes and resource use in
hemodialysis care: a prospective cohort study. BMC Health Serv Res 2007;
7: 5.
26. Lacson Jr E, Ikizler TA, Lazarus JM et al. Potential impact of nutritional
intervention on end-stage renal disease hospitalization, death, and
treatment costs. J Ren Nutr 2007; 17: 363–371.
27. Owen Jr WF, Lew NL, Liu Y et al. The urea reduction ratio and serum
albumin concentration as predictors of mortality in patients undergoing
hemodialysis. N Engl J Med 1993; 329: 1001–1006.
28. Eknoyan G, Levin NW, Steinberg E: The National Kidney Foundation
Dialysis Outcomes Quality Initiative. Curr Opin Nephrol Hypertens 1997; 6:
520–523.
29. Ofsthun NJ, Lazarus JM. Impact of the change in CMS billing rules for
erythropoietin on hemoglobin outcomes in dialysis patients. Blood Purif
2007; 25: 31–35.
30. Chan KE, Lazarus JM, Thadhani R et al. Anticoagulant and antiplatelet
usage associates with mortality among hemodialysis patients. J Am Soc
Nephrol 2009; 20: 872–881.
340 Kidney International (2009) 76, 331–341
or ig ina l a r t i c l e KE Chan et al.: Early post-hospitalization intervention
31. Charlson ME, Pompei P, Ales KL et al. A new method of classifying
prognostic comorbidity in longitudinal studies: development and
validation. J Chronic Dis 1987; 40: 373–383.
32. Miskulin DC, Martin AA, Brown R et al. Predicting 1 year mortality in an
outpatient haemodialysis population: a comparison of comorbidity
instruments. Nephrol Dial Transplant 2004; 19: 413–420.
33. van Manen JG, Korevaar JC, Dekker FW et al. How to adjust for
comorbidity in survival studies in ESRD patients: a comparison of
different indices. Am J Kidney Dis 2002; 40: 82–89.
34. Liang KY ZS. Longitudinal data analysis using generalized linear models.
Biometrika 2008; 73: 13–22.
35. Rosenbaum P, Rubin D. The central role of the propensity score
in observational studies for causal effect. Biometrika 1983; 70:
41–55.
36. Imbens G. The role of propensity score in estimating dose-response
in observational studies for causal effect. Biometrika 2000; 3: 706–710.
37. Rosenbaum PR. Model-based direct adjustment. J Am Stat Assoc 1987; 82:
387–394.
38. Hirano K IG. Estimation of causal effects using propensity score
weighting: an application to data on right heart catherization. Health Serv
Outcomes Res Methodol 2001; 2: 259–278.
39. Kosanke JBE. Gmatch: SAS macro. http://mayoresearch.mayo.edu/mayo/
research/biostat/upload, 2004.
40. Rubin D. Matching to remove bias in observational studies. Biometrics
1973; 29: 159–183.
41. Lau AH, How PP. The role of pharmacist in the identification and
management of secondary hyperparathyroidism. http://www.uspharmacist.
com/index.asp?page=ce/105514/default.htm, 2007. Ref Type: Journal (Full).
Kidney International (2009) 76, 331–341 341
KE Chan et al.: Early post-hospitalization intervention o r ig ina l a r t i c l e
